Cancer of the ovary, fallopian tube, and peritoneum

Jonathan S Berek; Sean Kehoe; Lalit Kumar; Michael Friedlander

doi:10.1002/ijgo.12614

Cancer of the ovary, fallopian tube, and peritoneum

Jonathan S Berek, Sean Kehoe, Lalit Kumar, Michael Friedlander

Cancer and Genomic Sciences

Research output: Contribution to journal › Article › peer-review

71 Citations (Scopus)

302 Downloads (Pure)

Abstract

The Gynecologic Oncology Committee of FIGO in 2014 revised the staging of ovarian cancer, incorporating ovarian, fallopian tube, and peritoneal cancer into the same system. Most of these malignancies are high-grade serous carcinomas (HGSC). Stage IC is now divided into three categories: IC1 (surgical spill); IC2 (capsule ruptured before surgery or tumor on ovarian or fallopian tube surface); and IC3 (malignant cells in the ascites or peritoneal washings). The updated staging includes a revision of Stage IIIC based on spread to the retroperitoneal lymph nodes alone without intraperitoneal dissemination. This category is now subdivided into IIIA1(i) (metastasis ≤10 mm in greatest dimension), and IIIA1(ii) (metastasis >10 mm in greatest dimension). Stage IIIA2 is now "microscopic extrapelvic peritoneal involvement with or without positive retroperitoneal lymph node" metastasis. This review summarizes the genetics, surgical management, chemotherapy, and targeted therapies for epithelial cancers, and the treatment of ovarian germ cell and stromal malignancies.

Original language	English
Pages (from-to)	59-78
Number of pages	20
Journal	International Journal of Gynecology & Obstetrics
Volume	143
Issue number	52
DOIs	https://doi.org/10.1002/ijgo.12614
Publication status	Published - 11 Oct 2018

Bibliographical note

Special Issue: FIGO Cancer Report 2018

Keywords

cancer statging
chemotherapy
fallopian tube
FIGO cancer reoprt
ovarian ovary
peritoneum

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/ijgo.12614Licence: Creative Commons: Attribution (CC BY)

Berek_et_al_Cancer_of_the_ovary_International_Journal_of_Gynecology_&_Obstetrics_2018Final published version, 1.57 MBLicence: Creative Commons: Attribution (CC BY)

https://obgyn.onlinelibrary.wiley.com/doi/full/10.1002/ijgo.12614Licence: Creative Commons: Attribution (CC BY)

Cite this

@article{aab03e03374d433991226d303bd3fb00,

title = "Cancer of the ovary, fallopian tube, and peritoneum",

abstract = "The Gynecologic Oncology Committee of FIGO in 2014 revised the staging of ovarian cancer, incorporating ovarian, fallopian tube, and peritoneal cancer into the same system. Most of these malignancies are high-grade serous carcinomas (HGSC). Stage IC is now divided into three categories: IC1 (surgical spill); IC2 (capsule ruptured before surgery or tumor on ovarian or fallopian tube surface); and IC3 (malignant cells in the ascites or peritoneal washings). The updated staging includes a revision of Stage IIIC based on spread to the retroperitoneal lymph nodes alone without intraperitoneal dissemination. This category is now subdivided into IIIA1(i) (metastasis ≤10 mm in greatest dimension), and IIIA1(ii) (metastasis >10 mm in greatest dimension). Stage IIIA2 is now {"}microscopic extrapelvic peritoneal involvement with or without positive retroperitoneal lymph node{"} metastasis. This review summarizes the genetics, surgical management, chemotherapy, and targeted therapies for epithelial cancers, and the treatment of ovarian germ cell and stromal malignancies.",

keywords = "cancer statging, chemotherapy, fallopian tube, FIGO cancer reoprt, ovarian ovary, peritoneum",

author = "Berek, {Jonathan S} and Sean Kehoe and Lalit Kumar and Michael Friedlander",

note = "Special Issue: FIGO Cancer Report 2018",

year = "2018",

month = oct,

day = "11",

doi = "10.1002/ijgo.12614",

language = "English",

volume = "143 ",

pages = "59--78",

journal = "International Journal of Gynecology & Obstetrics",

issn = "0020-7292",

publisher = "Elsevier",

number = "52",

}

TY - JOUR

T1 - Cancer of the ovary, fallopian tube, and peritoneum

AU - Berek, Jonathan S

AU - Kehoe, Sean

AU - Kumar, Lalit

AU - Friedlander, Michael

N1 - Special Issue: FIGO Cancer Report 2018

PY - 2018/10/11

Y1 - 2018/10/11

N2 - The Gynecologic Oncology Committee of FIGO in 2014 revised the staging of ovarian cancer, incorporating ovarian, fallopian tube, and peritoneal cancer into the same system. Most of these malignancies are high-grade serous carcinomas (HGSC). Stage IC is now divided into three categories: IC1 (surgical spill); IC2 (capsule ruptured before surgery or tumor on ovarian or fallopian tube surface); and IC3 (malignant cells in the ascites or peritoneal washings). The updated staging includes a revision of Stage IIIC based on spread to the retroperitoneal lymph nodes alone without intraperitoneal dissemination. This category is now subdivided into IIIA1(i) (metastasis ≤10 mm in greatest dimension), and IIIA1(ii) (metastasis >10 mm in greatest dimension). Stage IIIA2 is now "microscopic extrapelvic peritoneal involvement with or without positive retroperitoneal lymph node" metastasis. This review summarizes the genetics, surgical management, chemotherapy, and targeted therapies for epithelial cancers, and the treatment of ovarian germ cell and stromal malignancies.

AB - The Gynecologic Oncology Committee of FIGO in 2014 revised the staging of ovarian cancer, incorporating ovarian, fallopian tube, and peritoneal cancer into the same system. Most of these malignancies are high-grade serous carcinomas (HGSC). Stage IC is now divided into three categories: IC1 (surgical spill); IC2 (capsule ruptured before surgery or tumor on ovarian or fallopian tube surface); and IC3 (malignant cells in the ascites or peritoneal washings). The updated staging includes a revision of Stage IIIC based on spread to the retroperitoneal lymph nodes alone without intraperitoneal dissemination. This category is now subdivided into IIIA1(i) (metastasis ≤10 mm in greatest dimension), and IIIA1(ii) (metastasis >10 mm in greatest dimension). Stage IIIA2 is now "microscopic extrapelvic peritoneal involvement with or without positive retroperitoneal lymph node" metastasis. This review summarizes the genetics, surgical management, chemotherapy, and targeted therapies for epithelial cancers, and the treatment of ovarian germ cell and stromal malignancies.

KW - cancer statging

KW - chemotherapy

KW - fallopian tube

KW - FIGO cancer reoprt

KW - ovarian ovary

KW - peritoneum

U2 - 10.1002/ijgo.12614

DO - 10.1002/ijgo.12614

M3 - Article

C2 - 30306591

SN - 0020-7292

VL - 143

SP - 59

EP - 78

JO - International Journal of Gynecology & Obstetrics

JF - International Journal of Gynecology & Obstetrics

IS - 52

ER -

Cancer of the ovary, fallopian tube, and peritoneum

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this